This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Perception of bodily heaviness
Perception of bodily heaviness can be described as feelings of the body becoming extremely heavy.[1] This can result in one's body feeling as if it is difficult, uncomfortable, or sometimes impossible to move, resulting in feelings of slowness and sluggishness. This effect indirectly encourages feelings of sedation by making it uncomfortable or difficult to move.
Psychoactive substances
- 3-FEA
- 4-AcO-DMT
- 5-MeO-DMT
- 5F-PB-22
- AB-FUBINACA
- APICA
- Alprazolam
- Amanita muscaria
- Ayahuasca
- Bufotenin
- Cannabis
- Creatine
- Datura
- Diphenhydramine
- Flunitrazepam
- Gaboxadol
- Ibogaine
- JWH-018
- JWH-073
- Kava
- LSA
- LSM-775
- MCPP
- MDA
- MDEA
- MET
- Myristicin
- Psilocin
- Psilocybin mushrooms
- Quetiapine
- STS-135
- Temazepam
- Tizanidine
Experience reports
Anecdotal reports which describe this effect within our experience index include:
- Experience: 1.5g Psilocybe Cubensis - Analysis of body and mind
- Experience: 550mg DPH - My First Time on DPH
- Experience:1000 Morning Glory seeds - Rediscovering the Self
- Experience:1mg 25c-NBOMe - Experiment in my room
- Experience:300mg DPH + 600mg DXM - An Interesting Combo
- Experience:700mg - Joining the 700 club
- Experience:700mg Diphenhydramine trip
- Experience:Datura and nicotine smoked - 4 and ~15 hits; was actually quite pleasant
- Experience:LSA (20 HWBR seeds) – A pleasant adventure with a harsh body load
- Experience:Psilocybin Mushroom (0.16 g, Oral) - Dosage Independent Intensity
See also
- Responsible use
- Subjective effects index
- Perception of bodily lightness
- Deliriants - Subjective effects
- Psychedelics - Subjective effects
- Dissociatives - Subjective effects
References
- ↑ Espiard, M. L., Lecardeur, L., Abadie, P., Halbecq, I., & Dollfus, S. (2005). Hallucinogen persisting perception disorder after psilocybin consumption: a case study. European Psychiatry, 20(5), 458-460. https://doi.org/10.1016/j.eurpsy.2005.04.008